COVER

BIOCATALYSIS - Biocatalysis Without Barriers for Efficient Small Molecule Process Development

Masha Kononov and Reuben Carr examine both the promise and the practical constraints of biocatalysis in modern drug substance development, as well as the role of contract research, development and manufacturing organizations (CRD-MOs) in meeting the evolving demands of modern small molecule synthesis.

FEATURES

SPECIAL FEATURE - PFS & Parenteral Manufacturing: Rapid Growth of Injectables Places Unprecedented Demands on Parenteral Manufacturing

Contributor Cindy H. Dubin highlights many of these CDMOs as well as innovations in the PFS sector.

TKIS - Next-Generation BCR-ABL TKIs for CML: The Allosteric Era

Emil Kuriakose, MD, explores the current CML treatment landscape, ongoing clinical challenges, and the potential of next-generation TKIs currently in development, offering hope for the growing CML community.

SELF ADMINISTRATION - Smarter, Kinder, Simpler: EcoSafe Sets a New Standard for Sustainable Self-Administration

Mark Glass takes a novel approach to serve a patient group, with the ambitious aims of increasing the inclusivity of its existing 1mL safety syringe, simplifying procurement, reducing cost, and reducing carbon footprint.

EXCIPIENTS - Strategic Excipient Sourcing: Navigating Supply Chain Resilience, Quality & Sustainability by Design

Nick DiFranco, MEM, explores the critical considerations drug developers must evaluate when selecting an excipient partner today.

EXECUTIVE INTERVIEW - Resilience: From Complexity to Clarity - Sharpening Focus for Long-Term Performance in a More Demanding CDMO Era

Catherine Hanley, VP, Head of Marketing and Corporate Communications, explains how the company has rebalanced its network and aligned around its core strengths in biologics and sterile fill/finish manufacturing.

IPSC-NK THERAPIES - Advancing Allogeneic Platforms: The Future of Scalable iPSC-NK Therapies

Stefan Braam, PhD, explores how developers across the industry are tackling these challenges through process optimization, automation, and gene editing innovations. These efforts aim to deliver robust, cost-effective allogeneic platforms that meet the demands of modern healthcare.

EXECUTIVE INTERVIEW - Vetter Pharma: Why Fill-Finish Matters More Than Ever – & the Trends Behind It

Carsten Press, one of Vetter’s Managing Directors, discusses the key trends shaping CDMO innovation in today’s dynamic market – and how the family-owned company is integrating these trends into its forward-looking strategy to support consistent quality and seamless drug delivery.

CAR-T CELLS - The Growing Benefits of CAR-T Cells in Cancer Research & Beyond

Michael Kapinsky, PhD, says successful management or even curing a growing range of severe diseases, often lacking sufficient treatment options, seems to be in reach using CAR-engineered immune cells.

NASAL DELIVERY - Blazing a Trail to Patient-Friendly CNS Therapies: Exploring The Promise, Progress & Challenges of Nose-to-Brain Drug Delivery

Justin Lygrisse explores the rationale behind nose-to-brain delivery and the early clinical and preclinical efforts now underway to assess its potential.